

10/034,746

Refine Search

Search Results -

Terms	Documents
L8 and immunotherap\$	5

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L9

Refine Search

Recall Text

Clear

Interrupt

Search History

 DATE: Saturday, December 20, 2003 [Printable Copy](#) [Create Case](#)

<u>Set</u> <u>Name</u> side by side	<u>Query</u>	<u>Hit</u> <u>Count</u>	<u>Set</u> <u>Name</u> result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
<u>L9</u>	L8 and immunotherap\$	5	<u>L9</u>
<u>L8</u>	combretastatin and inhibit\$ near5 nitric near oxide near synthas\$	29	<u>L8</u>
<u>L7</u>	combretastatin near10 immun\$	5	<u>L7</u>
<u>L6</u>	combretastatin near10 immune\$	3	<u>L6</u>
<u>L5</u>	L4 and tumor\$ near5 induc\$ near5 immunosuppres\$	2	<u>L5</u>
<u>L4</u>	L3 and (enhance\$ or increa\$ or augment\$) near5 immune\$	18	<u>L4</u>
<u>L3</u>	L1 and vascular near5 (destruct\$ or damag\$)	65	<u>L3</u>
<u>L2</u>	L1 and vascular	683	<u>L2</u>
<u>L1</u>	combretastatin or combretastatin near (A or A4) or CA near (A4 or A) or CA4 or CA4P	6783	<u>L1</u>

END OF SEARCH HISTORY

Your wildcard search against 10000 terms has yielded the results below.

Your result set for the last L# is incomplete.

The probable cause is use of unlimited truncation. Revise your search strategy to use limited truncation.

[Generate Collection](#)

[Print](#)

Search Results - Record(s) 1 through 18 of 18 returned.

-
- ☐ 1. 20030211075. 27 Sep 02. 13 Nov 03. Combined compositions for tumor vasculature coagulation and treatment. Thorpe, Philip E., et al. 424/85.1; 514/12 514/323 514/54 514/733 A61K038/19 A61K031/739 A61K038/18 A61K031/454 A61K031/05.
-
- ☐ 2. 20030175276. 24 Feb 03. 18 Sep 03. Antibody methods for selectively inhibiting VEGF. Thorpe, Philip E., et al. 424/145.1; 435/7.2 A61K039/395 G01N033/53 G01N033/567.
-
- ☐ 3. 20030139374. 27 Sep 02. 24 Jul 03. Combined methods for tumor vasculature coagulation and treatment. Thorpe, Philip E., et al. 514/54; A61K031/739.
-
- ☐ 4. 20030129685. 18 Apr 01. 10 Jul 03. 12 human secreted proteins. Ni, Jian, et al. 435/69.1; 435/183 435/320.1 435/325 435/455 530/388.1 536/23.2 C12P021/02 C12N005/06 C07H021/04 C12N009/00 C07K014/435 C07K016/40.
-
- ☐ 5. 20030129193. 27 Sep 02. 10 Jul 03. Combined methods for tumor vasculature coagulant treatment. Thorpe, Philip E., et al. 424/155.1; 424/85.1 514/12 514/721 514/8 A61K039/395 A61K038/16 A61K038/19 A61K038/14 A61K031/075.
-
- ☐ 6. 20030124132. 27 Sep 02. 03 Jul 03. Combined compositions for tumor vasculature coagulant treatment. Thorpe, Philip E., et al. 424/178.1; 514/54 A61K039/395 A61K031/739.
-
- ☐ 7. 20030082187. 30 Nov 01. 01 May 03. Combined cancer treatment methods using antibodies to aminophospholipids. Thorpe, Philip E., et al. 424/155.1; A61K039/395.
-
- ☐ 8. 20020160973. 26 Dec 01. 31 Oct 02. Use of combretastatin A4 and its prodrugs as an immune enhancing therapy. Pero, Ronald W., et al. 514/44; 424/85.1 514/12 A61K048/00 A61K038/17 A61K038/19.
-
- ☐ 9. 20020119153. 30 Nov 01. 29 Aug 02. Antibody conjugate formulations for selectively inhibiting VEGF. Thorpe, Philip E., et al. 424/145.1; 424/133.1 530/388.24 A61K039/395 C07K016/22.
-
- ☐ 10. 6524583. 28 Apr 00; 25 Feb 03. Antibody methods for selectively inhibiting VEGF. Thorpe; Philip E., et al. 424/145.1; 424/133.1 424/135.1 424/141.1 530/387.1 530/388.1 530/388.15 530/388.25 530/809 530/864 530/865 530/866. A61K039/395 C12P021/08 C07K016/00.
-
- ☐ 11. 6416758. 28 Apr 00; 09 Jul 02. Antibody conjugate kits for selectively inhibiting VEGF. Thorpe; Philip E., et al. 424/145.1; 424/1.49 424/1.53 424/1.69 424/133.1 424/134.1 424/135.1 424/141.1 424/142.1 424/178.1 424/179.1 424/181.1 424/183.1 424/195.11 424/9.2 424/9.3 435/69.1 435/69.6 435/69.7 435/7.23 435/70.21 435/810 530/387.3 530/388.1 530/388.15 530/388.24 530/391.3

530/391.7 530/391.9. A61K038/36 C12P021/08 C07K016/22.

☐ 12. 6406693. 12 Jul 99; 18 Jun 02. Cancer treatment methods using antibodies to aminophospholipids. Thorpe; Philip E., et al. 424/130.1; 424/132.1 424/133.1 424/135.1 424/138.1 424/141.1 424/152.1 424/184.1 435/6 530/387.1. A61K039/395 C07K016/00 C07K016/28 C07K016/30 C12Q001/68.

☐ 13. 6342221. 28 Apr 00; 29 Jan 02. Antibody conjugate compositions for selectively inhibiting VEGF. Thorpe; Philip E., et al. 424/178.1; 424/1.49 424/1.53 424/130.1 424/179.1 424/181.1 424/183.1 424/193.1 424/195.11 424/9.3 424/9.34 424/9.6 435/69.1 435/7.1 435/7.21 435/7.23 435/70.21 435/810 530/391.1 530/391.3 530/391.5 530/391.7 530/391.9. A61K039/44 A61K039/395.

☐ 14. 6342219. 28 Apr 00; 29 Jan 02. Antibody compositions for selectively inhibiting VEGF. Thorpe; Philip E., et al. 424/145.1; 424/133.1 424/134.1 424/135.1 424/141.1 424/142.1 424/143.1 435/335 435/69.1 435/810 530/387.1 530/387.3 530/388.1 530/388.15 530/388.23 530/391.1 530/391.3 530/391.5 530/391.7 530/809 530/864 530/865 530/866. A61K039/395 C12P021/08 C07K016/00.

☐ 15. 6312694. 12 Jul 99; 06 Nov 01. Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids. Thorpe; Philip E., et al. 424/178.1; 424/133.1 424/134.1 424/135.1 424/136.1 424/137.1 424/141.1 424/142.1 424/143.1 424/181.1 424/193.1 514/12 530/387.1 530/388.1. A61K039/395 C12P021/08 C07K016/00.

☐ 16. 6080400. 13 Mar 97; 27 Jun 00. Compositions for the prevention and treatment of verotoxin-induced disease. Williams; James A., et al. 424/93.2; 424/241.1 424/93.4 424/93.48. A01N063/00 A61K039/108.

☐ 17. WO002058535A2. 26 Dec 01. 01 Aug 02. USE OF COMBRETASTATIN A4 AND ITS PRODRUGS AS AN IMMUNE ENHANCING THERAPY. PERO, RONALD W, et al. A61B00/;.

☐ 18. WO 200258535A. Use of combretastatin A4 and/or its prodrugs as an immune enhancing therapy for treating immunosuppression. EDVARSEN, K, et al. A61B000/00 A61K038/17 A61K038/19 A61K048/00.

Generate Collection

Print

Terms	Documents
L3 and (enhance\$ or increa\$ or augment\$) near5 immune\$	18

[Prev Page](#)

[Next Page](#)

[Go to Doc#](#)